A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
NCT ID: NCT06182969
Last Updated: 2025-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
40 participants
INTERVENTIONAL
2024-08-09
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
APG-2575
Dose escalation
APG-2575
Take orally once daily (QD) for 12 weeks.
Placebo
Placebo
Take orally once daily (QD) for 12 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
APG-2575
Take orally once daily (QD) for 12 weeks.
Placebo
Take orally once daily (QD) for 12 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 2\. On stable treatment for systemic lupus erythematosus before first dose at least 28 days.
* 3\. SLEDIA-2000 score: 4-12
* 4.Other than systemic lupus erythematosus, subject should be in general good health.
Exclusion Criteria
* 2\. Significant autoimmune disease other than lupus.
* 3\. Significant, uncontrolled or unstable disease in any organ.
18 Years
65 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Suzhou Yasheng Pharmaceutical Co., Ltd.
INDUSTRY
Ascentage Pharma Group Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sheng Chen, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Renji Hospital Shanghai Jiaotong University School of Medical
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Renji Hospital Shanghai Jiaotong University School of Medical
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APG2575SC101
Identifier Type: -
Identifier Source: org_study_id